This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

30 Dec 2011

Alexion Pharmaceuticals to Acquire Enobia Pharma

Alexion Pharmaceuticals plans to buy drug developer Enobia Pharma in a deal that could be worth $1.08 billion.

Alexion Pharmaceuticals Inc. said Wednesday it will buy drug developer Enobia Pharma Corp. in a deal that could be worth $1.08 billion.


Alexion will pay $610 million cash upfront for Enobia and as much as $470 million more based on regulatory and sales milestones.


Enobia is a privately held company based in Montreal and Cambridge, Mass. Its most advanced drug candidate is ENB-0040, an experimental treatment for hypophosphatasia.


ENB-0040 is in mid-stage clinical testing, and it has received orphan drug status in the U.S. and European Union, along with fast-track status in the U.S. Fast track reviews are intended to lead to faster decisions about drugs for serious illnesses or u

Related News